Liquidia (NASDAQ:LQDA) Insider Scott Moomaw Sells 9,539 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) insider Scott Moomaw sold 9,539 shares of the business’s stock in a transaction that occurred on Monday, July 13th. The stock was sold at an average price of $71.51, for a total transaction of $682,133.89. Following the completion of the transaction, the insider owned 182,485 shares of the company’s stock, valued at $13,049,502.35. This trade represents a 4.97% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Stock Up 7.4%

Shares of LQDA opened at $76.49 on Wednesday. The firm has a market capitalization of $6.80 billion, a price-to-earnings ratio of 546.40 and a beta of 0.55. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22. The business’s fifty day moving average price is $66.37 and its two-hundred day moving average price is $47.52. Liquidia Corporation has a 52 week low of $14.04 and a 52 week high of $82.96.

Liquidia (NASDAQ:LQDA) last released its earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.41 by $0.11. The company had revenue of $132.87 million during the quarter, compared to analysts’ expectations of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The firm’s revenue for the quarter was up 4187.1% compared to the same quarter last year. On average, analysts predict that Liquidia Corporation will post 3.02 earnings per share for the current year.

Hedge Funds Weigh In On Liquidia

Several institutional investors and hedge funds have recently made changes to their positions in LQDA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Liquidia by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock valued at $556,000 after buying an additional 1,700 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Liquidia by 10.7% during the first quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock worth $12,703,000 after acquiring an additional 82,955 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Liquidia by 15.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock worth $1,796,000 after acquiring an additional 16,022 shares in the last quarter. Creative Planning lifted its holdings in Liquidia by 40.7% during the second quarter. Creative Planning now owns 26,840 shares of the company’s stock worth $334,000 after acquiring an additional 7,765 shares in the last quarter. Finally, Legal & General Group Plc increased its holdings in shares of Liquidia by 13.4% in the second quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock worth $1,174,000 after acquiring an additional 11,111 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on LQDA. Zacks Research raised Liquidia from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 5th. BTIG Research raised their target price on shares of Liquidia from $59.00 to $109.00 and gave the company a “buy” rating in a research note on Monday, June 22nd. Needham & Company LLC lifted their price target on shares of Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Oppenheimer set a $75.00 price target on shares of Liquidia in a research note on Friday, June 5th. Finally, Bank of America restated a “neutral” rating and issued a $79.00 price objective (up from $64.00) on shares of Liquidia in a report on Monday, June 29th. Three equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Liquidia has a consensus rating of “Moderate Buy” and a consensus price target of $68.88.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Recent commentary notes that Liquidia’s Yutrepia has had a strong commercial debut, suggesting early traction in its pulmonary arterial hypertension market opportunity. Can LQDA’s Yutrepia Drive Growth in the Competitive PAH Market?
• Neutral Sentiment: An investor letter from Laughing Water Capital mentioned Liquidia in a broader portfolio update, but did not provide a clear company-specific catalyst. Here’s Laughing Water Capital’s Updates on Liquidia Corp. (LQDA)
• Negative Sentiment: Multiple insiders, including the CEO, CFO, general counsel, and other executives, sold shares on July 13 in pre-arranged 10b5-1 transactions tied to tax withholding from vesting equity awards. While these sales were planned and not necessarily a bearish signal, the size and breadth of the sales may still pressure investor sentiment. SEC filing – Roger Jeffs sale

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).